Background: The oestrogen antagonist tamoxifen has been suggested as an empiric treatment option for treating idiopathic oligoathenoteratozoospermia (iOAT). Objectives: To analyse the use of tamoxifen in iOAT. Method: Fifty-seven men receiving tamoxifen for iOAT were recruited from 2016 to 2017 in a retrospective, single-centre setting. Hormone and semen analysis was performed before and after 3 months of treatment. Results: After a 3-month treatment, serum levels of testosterone (3.4 ng/mL [2.7–4.8] vs. 5.3 [3.1–7.1]; p = 0.026), follicle stimulating hormone (FSH; 7.6 [5.9–11.5] vs. 15.9 mIU/mL [8.4–19.9]; p = 0.003) and luteinizing hormone (4.5 [3.3–6.6] vs. 7.6 mIU/mL [4.8–10.7]; p = 0.007) significantly increased. At a cut-off of >8.8 mIU/mL, serum levels of FSH were predictive for an improved sperm motility (OR 0.229 [95% CI 0.068–0.773]; p  = 0.018) and serum levels of inhibin B were predictive for an improved total sperm count at a cut-off of <82 ng/L (OR 18.0 [95% CI 1.267–255.744]; p = 0.033). During an 11 month-follow-up, patients receiving tamoxifen showed a clinical pregnancy rate of 42%, leading to a live birth rate of 56% of all pregnant women. Twenty-three per cent of all patients reported non-serious adverse events. Conclusions: Tamoxifen is effective in improving the total sperm count as well as motility and can thus be safely used as empiric medical therapy in iOAT.

Keywords:
Oestrogen antagonist, Tamoxifen, Sperm parameters, Idiopathic oligoathenoteratozoospermia
1.
Barratt CL, Björndahl L, De Jonge CJ, Lamb  DJ, Osorio Martini F, McLachlan R, et al. The diagnosis of male infertility: an analysis of the evidence to support the development of global WHO guidance-challenges and future research opportunities.
Hum Reprod Update
. 2017 Nov;23(6):660–80.
2.
Jungwirth A, Diemer T, Kopa Z, Krausz C. Minhas, Tournaye H. European Association of Urology Guidelines on Male Infertility: The 2018 Update. 2018 (cited December 21, 2018). Available from: https://uroweb.org/guideline/male-infertility/.
3.
World Health Organization. WHO laboratory manual for the Examination and processing of human semen, FIFTH EDITION. 2010 (cited December 11, 2018). Available from: http://apps.who.int/iris/bitstream/handle/10665/44261/9789241547789_eng.pdf;jsessionid=A71CF54CE1EDA03E2802769B938594F4?sequence=1.
4.
Chua ME, Escusa KG, Luna S, Tapia LC, Dofitas B, Morales M. Revisiting oestrogen antagonists (clomiphene or tamoxifen) as medical empiric therapy for idiopathic male infertility: a meta-analysis.
Andrology
. 2013 Sep;1(5):749–57.
5.
Kumar R, Gautam G, Gupta NP. Drug therapy for idiopathic male infertility: rationale versus evidence.
J Urol
. 2006 Oct;176(4 Pt 1):1307–12.
6.
Vandekerckhove P, Lilford R, Vail A, Hughes E, Hafez M. Clomiphene or tamoxifen for idiopathic oligo/asthenospermia.
Cochrane Database Syst Rev
. 1996;CD000151.
7.
Cavallini G. Male idiopathic oligoasthenoteratozoospermia.
Asian J Androl
. 2006 Mar;8(2):143–57.
8.
Cakan M, Aldemir M, Topcuoglu M, Altuğ U. Role of testosterone/estradiol ratio in predicting the efficacy of tamoxifen citrate treatment in idiopathic oligoasthenoteratozoospermic men.
Urol Int
. 2009;83(4):446–51.
9.
Guo L, Jing J, Feng YM, Yao B. Tamoxifen is a potent antioxidant modulator for sperm quality in patients with idiopathic oligoasthenospermia.
Int Urol Nephrol
. 2015 Sep;47(9):1463–9.
10.
Adamopoulos DA, Pappa A, Billa E, Nicopoulou S, Koukkou E, Michopoulos J: Effectiveness of combined tamoxifen citrate and testosterone undecanoate treatment in men with idiopathic oligozoospermia.
Fertil Steril
2003 Oct;80(4):914–20.
11.
Tsourdi E, Kourtis A, Farmakiotis D, Katsikis I, Salmas M, Panidis D. The effect of selective estrogen receptor modulator administration on the hypothalamic-pituitary-testicular axis in men with idiopathic oligozoospermia.
Fertil Steril
. 2009 Apr;91(4 Suppl):1427–30.
12.
Pulvers K, Scheuermann TS, Romero DR, Basora B, Luo X, Ahluwalia JS. Classifying a smoker scale in adult daily and nondaily smokers.
Nicotine Tob Res
. 2014 May;16(5):591–9.
13.
Ko EY, Siddiqi K, Brannigan RE, Sabanegh ES Jr. Empirical medical therapy for idiopathic male infertility: a survey of the American Urological Association.
J Urol
. 2012 Mar;187(3):973–8.
14.
Moein MR, Tabibnejad N, Ghasemzadeh J. Beneficial effect of tamoxifen on sperm recovery in infertile men with nonobstructive azoospermia.
Andrologia
. 2012 May;44 Suppl 1:194–8.
15.
Kadioglu TC. Oral tamoxifen citrate treatment is more effective in normogonadotropic patients who have follicle-stimulating hormone levels within the lower half of normal.
Int Urol Nephrol
. 2009 Dec;41(4):773–6.
16.
Nada EA, El Taieb MA, Ibrahim HM, Al Saied AE. Efficacy of tamoxifen and l-carnitine on sperm ultrastructure and seminal oxidative stress in patients with idiopathic oligoasthenoteratozoospermia.
Andrologia
. 2015 Sep;47(7):801–10.
17.
Kamischke A, Nieschlag E: Analysis of medical treatment of male infertility.
Hum Reprod
. 1999 Sep;14 Suppl 1:1–23.
18.
Wibowo E, Pollock PA, Hollis N, Wassersug RJ. Tamoxifen in men: a review of adverse events.
Andrology
. 2016 Sep;4(5):776–88.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.